Keryx Biopharmaceuticals (KERX) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Keryx Biopharmaceuticals (NASDAQ:KERX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01, MarketWatch Earnings reports.

Shares of KERX traded up $0.21 during midday trading on Friday, hitting $3.24. 3,342,206 shares of the stock traded hands, compared to its average volume of 1,100,369. Keryx Biopharmaceuticals has a 1-year low of $2.74 and a 1-year high of $5.98. The company has a market cap of $338.26 million, a price-to-earnings ratio of -3.68 and a beta of 2.46.

Several equities analysts have recently issued reports on KERX shares. Zacks Investment Research raised shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, August 28th. BidaskClub downgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, September 13th. HC Wainwright set a $9.00 price target on shares of Keryx Biopharmaceuticals and gave the company a “buy” rating in a report on Thursday, August 23rd. Finally, Citigroup reduced their price target on shares of Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating for the company in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $6.25.

A hedge fund recently raised its stake in Keryx Biopharmaceuticals stock. Bank of New York Mellon Corp grew its position in shares of Keryx Biopharmaceuticals (NASDAQ:KERX) by 10.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,056,811 shares of the biopharmaceutical company’s stock after acquiring an additional 102,014 shares during the quarter. Bank of New York Mellon Corp owned about 0.88% of Keryx Biopharmaceuticals worth $3,974,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 59.41% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Recommended Story: Asset Allocation

Earnings History for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply